[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sleeve-gastrectomy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sleeve-gastrectomy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,50,79,101,146,169,195,215,240,268,293,322,344,371,399,425],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100639694","pilot-study-of-salivary-bile-acids-and-pepsin-as-predictive-biomarkers-of-reflux-disease-after-sleeve-gastrectomy-100639694",false,"NCT07607067","Pilot Study of Salivary Bile Acids and Pepsin as Predictive Biomarkers of Reflux Disease After Sleeve Gastrectomy","Prospective Pilot Study of Salivary Bile Acids and Pepsin as Predictive Biomarkers of Reflux Disease and Esophageal Injury After Sleeve Gastrectomy","ABSORB","Inclusion Criteria:\n\n* Adults aged 18 years or older undergoing sleeve gastrectomy at a participating center.\n* Indication for obesity treatment with sleeve gastrectomy according to the 2022 ASMBS-IFSO consensus criteria, with a maximum body mass index (BMI) of 50 kg\u002Fm².\n* Approved for sleeve gastrectomy by the obesity multidisciplinary committee.\n* Ability and willingness to provide informed consent for biological sample collection and analysis.\n* Ability to understand and comply with scheduled follow-up visits.\n\nExclusion Criteria:\n\n* According to Lyon 2.0 criteria, participants with previous evidence of conclusive reflux disease, including Los Angeles grade B, C, or D esophagitis, peptic stricture, or Barrett's esophagus diagnosed before surgery.\n* Bariatric procedures other than sleeve gastrectomy, including Roux-en-Y gastric bypass or revisional bariatric surgery.\n* History of other preexisting esophageal diseases.\n* Previous esophageal surgery.\n* Active cholestatic hepatobiliary disease or treatment with bile acid sequestrants, ursodeoxycholic acid, or medications that significantly alter bile acid metabolism at the time of saliva sampling or within one month before sample collection.\n* Acute infection or systemic antibiotic treatment within four weeks before saliva sample collection.\n* Pregnancy or breastfeeding.",true,"ALL","18 Years","65 Years",{"count":22,"type":23},60,"ESTIMATED","3 Years","OBSERVATIONAL","The goal of this observational study is to learn whether bile acids and pepsin in saliva can help identify adults at higher risk of developing reflux-related esophageal disease after sleeve gastrectomy, including Los Angeles grade B-D erosive esophagitis and Barrett's esophagus. The study will include adults undergoing sleeve gastrectomy as part of their regular clinical care. Participants will be evaluated before and after surgery and will serve as their own comparison group over time.\n\nThe main questions it aims to answer are:\n\nAre saliva bile acids and pepsin linked to Los Angeles grade B-D erosive esophagitis or Barrett's esophagus after sleeve gastrectomy? How do saliva bile acids and pepsin change before and after sleeve gastrectomy? Can saliva bile acids and pepsin become useful biomarkers for detecting reflux-related esophageal disease after sleeve gastrectomy? Are saliva biomarker levels linked to reflux symptoms and endoscopy results after surgery?\n\nResearchers will compare saliva biomarker levels before and after surgery and between participants with and without reflux-related esophageal disease.\n\nParticipants will:\n\nProvide saliva samples before surgery and at 12 and 36 months after surgery Provide fasting and post-meal saliva samples Undergo routine postoperative clinical follow-up and upper gastrointestinal endoscopy Complete reflux symptom questionnaires during follow-up\n\nThe study will also explore whether saliva biomarkers could help select participants for follow-up endoscopy after sleeve gastrectomy.",[28,29,30,31,32],"Reflux Disease, Gastro-Esophageal","Sleeve Gastrectomy","Saliva Collection","Reflux Esophagitis (RE)","Barrett Esophagus",[34,35,36,37,32],"sleeve gastrectomy","bile acid reflux","salivary biomarkers","erosive esophagitis","NOT_YET_RECRUITING","2026-05-19",{"date":41,"type":42},"2026-05-26","ACTUAL",{"date":44,"type":23},"2026-12",{"date":46,"type":23},"2029-12",{"name":48,"class":49},"Hospital de Mataró","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":57,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100637643","intertransverse-process-block-versus-external-oblique-intercostal-plane-block-after-laparoscopic-sleeve-gastrectomy-100637643","NCT07591116","Intertransverse Process Block Versus External Oblique Intercostal Plane Block After Laparoscopic Sleeve Gastrectomy","Intertransverse Process Block Versus External Oblique Intercostal Plane Block for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 18-65 years\n* ASA physical status I-III\n* Scheduled for elective laparoscopic sleeve gastrectomy\n* Body mass index (BMI) \\>35 kg\u002Fm²\n* Ability to understand and use the patient-controlled analgesia (PCA) device\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Refusal to participate\n* Allergy to local anesthetics\n* Infection at the injection site\n* Coagulopathy or ongoing anticoagulant therapy\n* Chronic opioid use or opioid dependence\n* Severe hepatic or renal insufficiency\n* Pregnancy or breastfeeding\n* Cognitive impairment or inability to communicate pain scores\n* Body mass index (BMI) \\>35 kg\u002Fm²",{"count":22,"type":23},"INTERVENTIONAL",[60],"NA","This randomized clinical trial aims to evaluate and compare the analgesic efficacy of the Intertransverse Process Block (ITPB) and the Subcostal External Oblique Intercostal Plane Block (EOIPB) in patients undergoing laparoscopic sleeve gastrectomy. The primary outcome is the Visual Analog Scale (VAS) score within the first 24 hours after surgery. Secondary outcomes include total opioid consumption, requirement for rescue analgesia, block-related complications and adverse effects (hematoma, pneumothorax, local anesthetic systemic complications, vascular puncture, and infection), patient satisfaction assessed using a Likert scale, quality of recovery assessed using the QoR-15 questionnaire, and incidence of postoperative nausea and vomiting.",[63,64,29,65,66],"Intertransverse Process Block","External Oblique Intercostal Plane Block","Regional Anaesthesia","Postoperative Pain",[68,69],"ITP","EOIPB","2026-05-09",{"date":72,"type":42},"2026-05-15",{"date":74,"type":23},"2026-12-15",{"date":76,"type":23},"2027-12-30",{"name":78,"class":49},"Antalya City Hospital",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":85,"targetDuration":4,"studyType":58,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100638217","intertransverse-process-block-versus-subcostal-transversus-abdominis-plane-block-after-laparoscopic-sleeve-gastrectomy-100638217","NCT07591129","Intertransverse Process Block Versus Subcostal Transversus Abdominis Plane Block After Laparoscopic Sleeve Gastrectomy","Intertransverse Process Block Versus Subcostal Transversus Abdominis Plane Block for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy: A Prospective Randomized Controlled Trial",{"count":22,"type":23},[60],"This randomized clinical trial aims to evaluate and compare the analgesic efficacy of the Intertransverse Process Block (ITPB) and the Subcostal Transversus Abdominis Plane Block (TAPB) in patients undergoing laparoscopic sleeve gastrectomy. The primary outcome is the Visual Analog Scale (VAS) score within the first 24 hours after surgery. Secondary outcomes include total opioid consumption, requirement for rescue analgesia, block-related complications and adverse effects (hematoma, pneumothorax, local anesthetic systemic complications, vascular puncture, and infection), patient satisfaction assessed using a Likert scale, quality of recovery assessed using the QoR-15 questionnaire, and incidence of postoperative nausea and vomiting.",[63,89,29,66,65],"Subcostal Transverse Abdominis Plane Block",[68,91,92,93],"TAP","PAİN","SLEEVE GASTRECTOMİ",{"date":72,"type":42},{"date":96,"type":23},"2026-12-30",{"date":98,"type":23},"2028-05-30",{"name":78,"class":49},1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":18,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":58,"phases":112,"briefSummary":113,"conditions":114,"keywords":133,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":100},"100567703","stanford-program-to-accelerate-robotic-childrens-surgery-100567703","NCT06671639","Stanford Program to Accelerate Robotic Children's Surgery","SPARCS","Inclusion Criteria:\n\n1. Subject is between 6 - 21 years of age (weighing at least 15 kilograms)\n2. Subject clinically diagnosed with a medical condition for which one of the study procedures is appropriate therapy and selected as the treatment of choice by the guardian and surgeon.\n3. Subject without previous treatment using a robotic surgery device\n4. Subject or their guardian is willing and able to provide written informed consent\n5. Subject or their guardian is willing and able to comply with the study protocol requirements\n\nExclusion Criteria:\n\n1. Subject with uncorrected coagulopathy\n2. Subject has clinical requirement for primary open operative procedure\n3. Subject is ASA 4 or 5 status\n4. Subject is contraindicated for general anesthesia or surgery\n5. Subject is mentally handicapped or has a psychological disorder or severe systemic illness that would preclude compliance with study requirements or ability to provide informed consent\n6. Subject is pregnant or suspected to be pregnant","6 Years","21 Years",{"count":111,"type":23},250,[60],"The goal of this clinical trial is to provide additional data to confirm safety and performance of the da Vinci Xi Surgical System in a human clinical setting. This pilot study is intended to provide an initial assessment to evaluate the feasibility, safety, and effectiveness for the utilization of the da Vinci Xi on pediatric and adolescent patients. This clinical trial will be conducted under the auspices of Stanford University's IRB approval.",[29,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132],"Cholecystectomy","Splenectomy","Hysterectomy","Endometriosis","Ureteral Re-implant","Cervical and Thoracic Tracheoplasty","Thymectomy","Lobectomy\u002FWedge Lung Resection","Lung Segmentectomy","Bronchoplasty","Endoscopic Laryngeal\u002FPharyngeal Suturing","Vocal Feminization","Laryngeal Cleft Repair","Endolaryngeal Adjacent Tissue Transfer","Pharyngoplasty","Ileocolonic Resections","Laryngoplasty","Proctectomy With Ileal Pouch-Anal Anastomosis",[134,135],"Robotic Surgery","Pediatric Robotic Surgery","RECRUITING","2026-04-24",{"date":139,"type":42},"2026-04-30",{"date":141,"type":42},"2025-08-01",{"date":143,"type":23},"2028-02-28",{"name":145,"class":49},"Stanford University",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":152,"targetDuration":4,"studyType":58,"phases":154,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":100},"100635022","comparison-of-the-effects-of-external-oblique-intercostal-plane-block-and-subcostal-transversus-plane-block-methods-with-ultrasound-guidance-on-postoperative-analgesia-in-laparoscopic-sleeve-gastrectomy-operations-100635022","NCT07547280","Comparison of the Effects of External Oblique Intercostal Plane Block and Subcostal Transversus Plane Block Methods With Ultrasound Guidance on Postoperative Analgesia in Laparoscopic Sleeve Gastrectomy Operations","Inclusion Criteria:\n\n* Adult patients aged between 18 and 65 years\n* Patients classified as American Society of Anesthesiologists (ASA) physical status I-III\n\nExclusion Criteria:\n\n* Patients younger than 18 years or older than 65 years\n* Inability to cooperate or comply with study procedures\n* Liver and kidney failure\n* American Society of Anesthesiologists (ASA) IV-V patient\n* External oblique intercostal block(EOİB) and the Subcostal Transversus Abdominis Plane block(s-TAB) are contraindicated",{"count":153,"type":23},90,[60],"The primary aim of this study was to investigate the effects of the external oblique intercostal plane block and the subcostal transversus abdominis plane block on postoperative pain scores and opioid consumption in patients undergoing laparoscopic sleeve gastrectomy.",[29,64,89],[158],"Ultrasound guided · External oblique intercostal plane block · Sleeve gastrectomy Bariatric surgery Postoperative · Analgesia","2026-04-20",{"date":161,"type":42},"2026-04-23",{"date":163,"type":23},"2026-04-01",{"date":165,"type":23},"2027-05-01",{"name":167,"class":168},"Sanliurfa Education and Research Hospital","OTHER_GOV",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":177,"targetDuration":4,"studyType":58,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":194},"100576319","mechanistic-and-clinical-outcomes-of-a-surgical-innovation-aimed-at-minimizing-gerd-associated-with-vsg-innovate-vsg-100576319","NCT06783751","Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)","Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With Vertical Sleeve Gastrectomy (INNOVATE-VSG)","INNOVATE-VSG","Inclusion Criteria:\n\n1. Male and female subjects aged 18-65 years\n2. Body mass index (BMI) 35-55 kg\u002Fm2\n3. Must meet the BMI criteria before and after 6 months of nonsurgical weight management\n4. Presence of GERD defined for this trial as acid exposure time (AET) of 4.9% or above as assessed with the Bravo pH test.\n5. Have health insurance which pays for the costs of bariatric surgery and standard medical care before and after surgery\n6. Women of childbearing potential must be using appropriate contraception to avoid pregnancy throughout the study, and must have a negative pregnancy test at study entry and prior to surgery\n7. Must be able to provide written informed consent\n\nExclusion Criteria:\n\n1. Hiatal hernia \\>2cm (defined as maximum axial height from end of the esophagus to diaphragm by any study including upper endoscopy esophagram and or at the time of surgery)\n2. Evidence of clinically significant major esophageal motility disorder as determined by the site primary investigator\n3. Severe gastroparesis\n4. Previous bariatric or anti-reflux procedure\n5. Barrett's esophagus\n6. Subjects requiring mesh treatment at time of procedure\n7. Severe heart (e.g., severe heart failure, unstable coronary artery disease), or end-stage lung disease as determined by the site primary investigator\n8. Subjects with pacemakers, implantable defibrillators, neurostimulators\n9. Portal hypertension or cirrhosis\n10. Chronic pancreatitis\n11. Active cancer treatment\n12. Inability to tolerate general anesthesia\n13. Uncontrollable coagulopathy\n14. Significant and uncontrolled inflammatory bowel disease\n15. Severe and\u002For uncontrolled psychiatric disorder (including psychosis, bipolar disorder) as determined during standard pre-surgery psychiatric screening at the site.\n16. Suicidal ideation or unstable\u002Funtreated major depressive disorder within the past year\n17. Alcohol or substance use disorder within the past year.\n18. Pregnant or breastfeeding or planning pregnancy in the coming 24 months\n19. Diminished intellectual capacity to consent or follow pre- and post-surgery instructions\n20. History of, or any current health condition that, in the opinion of the PI, would make the subject ineligible for sleeve gastrectomy, or put the subject at risk by participation in the study.",{"count":178,"type":23},44,[60],"This is a two-site randomized clinical trial aiming to test whether a modified investigational bariatric surgical procedure can improve gastroesophageal reflux disease (GERD) after sleeve gastrectomy.",[182,183,29,184],"Obesity","Bariatric Surgery","Gastroesophageal Reflux Disease","2026-04-08",{"date":187,"type":42},"2026-04-13",{"date":189,"type":42},"2025-03-21",{"date":191,"type":23},"2027-07-31",{"name":193,"class":49},"University of California, Irvine",2,{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":58,"phases":203,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":211,"leadSponsor":213,"locationsCount":100},"100617028","impact-of-foot-reflexology-on-nausea-after-obesity-surgery-100617028","NCT07313293","Impact of Foot Reflexology on Nausea After Obesity Surgery","IRANNO","Inclusion Criteria:\n\n* Adult patient\n* Patient scheduled to undergo sleeve gastrectomy\n* Patient capable of understanding the protocol and having given their informed verbal consent to participate in the study\n* Patient affiliated with the social security system or entitled to benefits\n\nExclusion Criteria:\n\n* Patients receiving long-term morphine and opioid treatment\n* Patients with phlebitis, a wound under the foot, or recent foot trauma (cast immobilisation, splint, etc.)\n* Patients under guardianship, curatorship, or deprived of their liberty\n* Patients who are pregnant, breastfeeding, or refusing contraception\n* Patients participating in another clinical research protocol that has an impact on the objective of the study\n* Patients under an activated future protection mandate\n* Patients under family authorisation\n* Patients under judicial protection",{"count":22,"type":23},[60],"Obesity is a major public health issue. The Obépi epidemiological survey, the results of which were published in 2020, shows a steady increase in obesity among the French population.\n\nCurrently, more than 23 million French people are overweight or obese, and more than 8 million French people are obese. The most effective treatment currently available is surgery. These procedures are governed by specific recommendations. Between 50,000 and 60,000 procedures are performed in France each year. Three procedures are authorised: gastric banding, sleeve gastrectomy and gastric bypass.\n\nHallyday \\& al report 65% of patients experiencing nausea\u002Fvomiting after bariatric surgery. In 2019, Suh \\& al showed that nausea and vomiting were more common after sleeve gastrectomy and that they were responsible for an increase in the length of hospitalisation. These episodes of nausea and vomiting occur within 48 hours after sleeve gastrectomy and can cause difficulties in resuming eating. One of the factors contributing to the occurrence of nausea and vomiting was the use of opioids.\n\nThe benefits of foot reflexology were reported in 2023 by Dr Carrazé in rectal surgery. His doctoral thesis in medicine showed that foot reflexology sessions on days 1, 2 and 3 following rectal surgery reduced post-operative ileus and post-operative pain. The reduction in post-operative ileus led to a decrease in episodes of nausea and vomiting.\n\nIn 2021, Murat-Ringot \\& al demonstrated the beneficial effect of foot reflexology on nausea and vomiting during chemotherapy sessions, in addition to the anti-emetic treatments used for prevention. Anderson \\& al. in 2021 also demonstrated a beneficial effect on pain in cancer patients, with no effect on nausea.\n\nThe principle of foot reflexology is based on the fact that each organ, gland or part of the body corresponds to a reflex zone on the foot, hand, ears or face. Stimulation of the reflex zones is thought to activate the autonomic nervous system. Currently, there is very little scientific evidence on how this practice works and what its effects are. Despite various scientific publications on the results of foot reflexology, scientific evidence of its effectiveness remains weak. Only one prospective randomised trial has been found in the literature (Dalal \\& al.) on the quality of life of patients with epilepsy.\n\nDespite the lack of high-quality studies, it appears that foot reflexology could benefit patients by reducing nausea and vomiting. To date, no studies have evaluated its effectiveness in the post-operative period, particularly after bariatric surgery.\n\nThe aim of our randomised trial is to evaluate the impact of foot reflexology on nausea and vomiting after sleeve gastrectomy.",[29],[207],"foot reflexology",{"date":209,"type":42},"2026-04-02",{"date":163,"type":42},{"date":212,"type":23},"2028-07-03",{"name":214,"class":49},"Centre Hospitalier Departemental Vendee",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":58,"phases":224,"briefSummary":225,"conditions":226,"keywords":229,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":194},"100394112","post-sleeve-gastrectomy-gastroesophageal-reflux-disease-prediction-100394112","NCT04411823","Post-sleeve Gastrectomy Gastroesophageal Reflux Disease Prediction","Prediction of Post-laparoscopic Sleeve Gastrectomy Gastroesophageal Reflux Disease With an Endolumenal Functional Lumen Imaging Probe (EndoFLIP)","Inclusion Criteria:\n\n* Adult patients \\> 18 years\n* BMI 30 or greater kg\u002Fm2\n* Participants can give a consent to the procedure\n* Participants have no contraindications to LSG (gastric ulceration)\n\nExclusion Criteria:\n\n* Participants who have LA grade C or D esophagitis, Barrett mucosa or peptic stricture.\n* Patients who have evidence of a major motility abnormality defined by the Chicago classification version 3.0 (achalasia, absent contractility, esophagogastric junction outflow obstruction, distal esophageal spasm, or hypertensive peristalsis)\n* Patients with hiatal hernia \\> 3 cm\n* Patients with previous esophageal or stomach surgery",{"count":223,"type":23},200,[60],"Researchers are trying to identify predictors for gastroesophageal reflux disease after sleeve gastrectomy.",[227,29,228],"Gastroesophageal Reflux","Bariatric Surgery Complication",[227,230],"Sleeve gastrectomy","2026-03-03",{"date":233,"type":42},"2026-03-05",{"date":235,"type":42},"2021-02-01",{"date":237,"type":23},"2028-10",{"name":239,"class":49},"Mayo Clinic",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":247,"targetDuration":249,"studyType":25,"phases":4,"briefSummary":250,"conditions":251,"keywords":253,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":100},"100623510","iron-supplementation-and-anemia-after-sleeve-gastrectomy-100623510","NCT07397572","Iron Supplementation and Anemia After Sleeve Gastrectomy","Prophylactic Oral Iron Supplementation for the Prevention of Iron Deficiency Anemia After Sleeve Gastrectomy: A Prospective Comparative Cohort Study","Inclusion Criteria:\n\n* Adults aged 18 to 65 years scheduled to undergo primary laparoscopic sleeve gastrectomy (LSG).\n* Capable of understanding and providing written informed consent for participation.\n* Able and willing to commit to the 6-month post-operative follow-up schedule at the bariatric clinic.\n\nExclusion Criteria:\n\n* Prior history of major gastrointestinal surgery (e.g., bowel resection, gastrectomy) that could independently affect iron absorption.\n* Pre-existing malabsorptive conditions (e.g., inflammatory bowel disease, celiac disease).\n* Diagnosis of other known forms of anemia (e.g., thalassemia, vitamin B12\u002Ffolate deficiency, anemia of chronic disease) that would confound the diagnosis of iron deficiency anemia (IDA).\n* Any condition that, in the investigator's judgment, would interfere with full participation in the study or pose a significant risk.",{"count":248,"type":23},66,"6 Months","The goal of this observational study is to learn if taking extra iron pills after weight loss surgery helps prevent low iron and anemia compared to just taking a standard multivitamin. The main question it aims to answer is:\n\nDoes a specific iron supplementation plan lower the number of patients who develop iron deficiency anemia in the 6 months after sleeve gastrectomy surgery?\n\nResearchers will compare two groups of patients from different hospital units to see if the extra iron works:\n\nPatients from one unit who take a prophylactic iron supplement (Ferrodep, 60 mg per day) in addition to their standard multivitamin.\n\nPatients from another unit who take only a standard multivitamin (Centrum Silver).\n\nParticipants in this study will:\n\n* Have their blood tested for iron and anemia levels before surgery, and again at 3 and 6 months after surgery, as part of their regular post-operative care.\n* Be asked about their health and quality of life during follow-up clinic visits.\n* Have their medical information from their hospital records reviewed by the study team to track their progress.",[252,182,29],"Iron Deficiency Anemia",[254,183,252,255,256,257,258],"Laparoscopic Sleeve Gastrectomy","Iron Supplementation","Multivitamin","Morbid Obesity","Observational Study","2026-02-07",{"date":261,"type":42},"2026-02-11",{"date":263,"type":42},"2026-01-17",{"date":265,"type":23},"2027-01",{"name":267,"class":49},"Cairo University",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":275,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":277,"conditions":278,"keywords":281,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":100},"100615005","gastro-intestinal-digestion-and-physiology-after-bariatric-surgery-100615005","NCT07286968","Gastro-Intestinal Digestion and Physiology After Bariatric Surgery","GIBa","Inclusion Criteria:\n\nParticipants eligible for inclusion in this Investigation have to meet all of the following criteria:\n\n1. Voluntary written informed consent of the participant has been obtained prior to any screening procedures\n2. Age: 18-65 years\n\n   Specific inclusion criteria for the different patient populations:\n\n   Patients with obesity:\n3. Body Mass Index: \\> 30 kg\u002Fm2\n\n   Patients after bariatric surgery:\n4. Surgery: at least one year after Roux-en-Y gastric bypass or sleeve gastrectomy\n\nExclusion Criteria:\n\nParticipants eligible for this Investigation must not meet any of the following criteria:\n\n1. Patient has history of more than one bariatric surgery\n2. Patient has a waist circumference \\> 125.6 cm\n3. Patient had gastrointestinal surgery in the past three months\n4. Patient has a pacemaker, defibrillator, infusion pump, or other portable or implanted electromedical device\n5. Patient had frequent exposure to X-rays in the past year\n6. Patient has swallowing disorders, among others: dysphagia for food or pills, any oropharyngeal or oesophageal stricture, anxiety or functional abnormality\n7. Patient has Crohn's disease or Diverticulitis\n8. Patient has gastrointestinal strictures, fistulas or physiological\u002Fmechanical obstructions\n9. Patient has gastric bezoar\n10. Patient has a history of complex bowel resection or known abdominal adhesions\n11. Patient has short bowel syndrome or ostomy\n12. Patient has currently ongoing infections\n13. Patient is planned to undergo usage of rectal foam\u002Fenema or treatment with adjuvant chemotherapy or radiotherapy\n14. Patient is currently on parenteral diet\n15. Patient is planned to undergo MRI procedure during usage of the wireless capsule\n16. Patient is working in a professional healthcare facility (e.g. hospital, dental office, emergency room), military area (e.g. submarine, near radar installation), or heavy industrial area (e.g. power plants, automotive, mining, refineries) during the duration of the clinical investigation\n17. Patient is pregnant, breastfeeding, actively trying to get pregnant or had recent childbirth in last 6 months\n18. Patient cannot discontinue medication that affects gastrointestinal transit time and\u002For pH for at least 3 days before and during the study (and 4 weeks for weekly\u002Flong-acting GLP-1 analogues such as Saxenda, Ozempic, Wegovy, Mounjaro). This includes opioids (e.g., morphine, codeine), proton pump inhibitors (e.g., omeprazole, esomeprazole, pantoprazole), H2-receptor antagonists (e.g., cimetidine, famotidine), antacids, sucralfate, prokinetics (e.g., domperidone, metoclopramide), antidiarrheal agents (e.g., loperamide), antibiotics, probiotics and prebiotics.\n19. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the CIP.",{"count":276,"type":23},51,"The goal of this clinical trial is to characterize gastrointestinal digestion and physiology in patients after bariatric surgery, or people living with obesity. The main question it aims to answer is: what is the status of gastrointestinal digestion and physiology after bariatric surgery? Participants will have two study visits: 1) participants will undergo collection of gastrointestinal samples and 2) participants will ingest an ingestible capsule that measures multiple physiological parameters along the gastrointestinal tract.",[183,279,29,280],"Roux-en Y Gastric Bypass","Obesity & Overweight",[282,283],"Gastro-intestinal aspiration","ingestible telemetric capsule","2026-01-15",{"date":286,"type":42},"2026-01-20",{"date":288,"type":23},"2026-01-10",{"date":290,"type":23},"2027-07-01",{"name":292,"class":49},"Universitaire Ziekenhuizen KU Leuven",{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":304,"conditions":305,"keywords":309,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":194},"100582875","study-of-the-link-between-mash--metabolic-dysfunction-associated-steatohepatitis-and-mams-mitochondria-associated-membranes--alteration-in-patients-undergoing-bariatric-surgery---mamba-100582875","NCT06868992","Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA","Study of the Link Between Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Mitochondria-Associated Membranes (MAMs) Alteration in Patients Undergoing Bariatric Surgery - MAMBA","MAMBA","* Inclusion Criteria \\* :\n\n  * Female or male adult patients\n  * Patient who has benefited from a pluridisciplinary evaluation (medical, surgical, psychiatric), with a favorable opinion for a sleeve gastrectomy or a gastric bypass.\n  * Patient with an indication Indication for intraoperative liver biopsy due to suspected MASH\n  * Patient who agrees to be included in the study and who signs the informed consent form,\n  * Patient affiliated to a healthcare insurance plan.\n* Exclusion Criteria \\* :\n\n  * Patient presenting Hepatitis B as defined as presence of hepatitis B surface antigen (HBsAg).\n  * Patient presenting previous or current infection with Hepatitis C\n  * Autoimmune hepatitis as defined by anti-nuclear antibody (ANA) of 1:160 or greater and liver histology consistent with autoimmune hepatitis or previous response to immunosuppressive therapy.\n  * Patient presenting Autoimmune cholestatic liver disorders as defined by elevation of alkaline phosphatase and anti-mitochondrial antibody of greater than 1:80 or liver histology consistent with primary biliary cirrhosis or elevation of alkaline phosphatase and liver histology consistent with sclerosing cholangitis.\n  * Patient presenting Wilson disease as defined by ceruloplasmin below the limits of normal and liver histology consistent with Wilson disease.\n  * Patient presenting Alpha-1-antitrypsin deficiency as defined by alpha-1-antitrypsin level less than normal and liver histology consistent with alpha-1-antitrypsin deficiency.\n  * Patient presenting Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy and homozygosity for C282Y or compound heterozygosity for C282Y\u002FH63D.\n  * Patient presenting Drug-induced liver disease as defined on the basis of typical exposure and history.\n  * Patient presenting Bile duct obstruction as shown by imaging studies.\n  * History of ingestion of medications known to produce steatosis, such as corticosteroids, high-dose estrogen, tamoxifen, methotrexate, amiodarone or tetracycline in the previous 6 months.\n  * Evidence of cirrhosis or previously known cirrhosis based on the results from previous liver biopsy or history of portal hypertension presented by ascites, hepatic encephalopathy or varices\n  * Consommation régulière et\u002Fou excessive d'alcool (plus de 30g\u002Fj pour les hommes et plus de 15 g\u002Fj pour les femmes) sur une période de plus de 2 ans au cours des 10 dernières années.\n  * History of known HIV infection\n  * History of type 1 diabetes\n  * Pregnant women or breastfeeding mothers\\*.\n  * Minor patient\n  * Patient deprived of liberty,\n  * Patients under psychiatric care\n  * Patients admitted to a health or social care establishment for purposes other than research\n  * Mentally unbalanced patients, under supervision or guardianship,\n  * Patients not affiliated to a social security scheme or benefiting from a similar scheme\n  * Patient who does not understand French\u002F is unable to give consent,\n  * Patient already included in a trial who may interfere with the study","99 Years",{"count":303,"type":23},20,"The main research hypothesis is that alterations in the communication between the endoplasmic reticulum (ER) and the mitochondria at contact sites called mitochondria-associated membranes (MAMs) occurs in different hepatic cell types of patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MALSD) and is involved in the progression towards MASH and could also influence the process of improvement of MASH.\n\nThis study aims to investigate the link between Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Mitochondria-Associated Membranes (MAMs) in liver cells and peripheral blood mononuclear cells (PBMCs) in patients undergoing bariatric surgery. The primary objective is to analyze MAMs alterations in hepatocytes in MASH patients compared to non-MASH patients. Secondary objectives include evaluating the correlation between MAMs in PBMCs and liver cells and assessing MAMs changes post-bariatric surgery.",[306,307,29,308],"Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Dysfunction-Associated Steatohepatitis","Gastric Bypass Surgery",[310,311,312,183,313],"MASH","MASLD","Mitochondria-Associated Membranes (MAMs)","Hepatic Fibrosis","2026-01-14",{"date":284,"type":42},{"date":317,"type":42},"2025-04-15",{"date":319,"type":23},"2028-03",{"name":321,"class":49},"Hospices Civils de Lyon",{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":329,"targetDuration":4,"studyType":58,"phases":331,"briefSummary":332,"conditions":333,"keywords":334,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":341,"locationsCount":100},"100552557","powered-handle-primary-sleeve-gastrectomy-study-100552557","NCT06474637","Powered Handle Primary Sleeve Gastrectomy Study","Prospective Clinical Evaluation of the AEON Endoscopic Stapler Powered Handle and Reload in Primary Sleeve Gastrectomy","Inclusion Criteria:\n\n1. Be within the range of 18-65 years of age\n2. Patients undergoing primary sleeve gastrectomy procedures\n3. Psychosocially, mentally, and physically able to comply with protocol, post-operative management and follow-up schedule.\n\nExclusion Criteria:\n\n1. Prior bariatric surgery procedure\n2. Sleeve gastrectomy procedure that is planned to be performed via open approach\n3. Patients receiving anticoagulant medication(s)\n4. Severe heart disease or lung problems\n5. Known sensitivity to implant materials\n6. Evidence of active (systemic or localized) infection at time of surgery\n7. Women who are pregnant or planning to get pregnant in the next 12 months\n8. Recent history of known alcohol and\u002For narcotic abuse\n9. Investigational drug or device use within 30 days\n10. Any other factors that may contribute, based on professional judgement of the treating surgeon, to the subject being a poor candidate for the study",{"count":330,"type":23},100,[60],"The objective of this prospective, single arm, single-center study is to evaluate patients who are undergoing primary sleeve gastrectomy procedures and are surgically treated with the AEON Endoscopic Powered Handle Stapler and Stapler Reload. The primary endpoint is to assess the percentage of patients who encountered post-operative staple line complications (bleeding or leak), defined as requiring blood transfusion or revision surgery due to staple line complications.",[29],[335],"LSG (Laparoscopic Sleeve Gastrectomy)","2026-01-13",{"date":314,"type":42},{"date":339,"type":42},"2024-01-30",{"date":319,"type":23},{"name":342,"class":343},"Lexington Medical Inc.","INDUSTRY",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":350,"targetDuration":4,"studyType":58,"phases":351,"briefSummary":353,"conditions":354,"keywords":358,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":194},"100272246","early-phase-1-the-effects-of-bariatric-surgeries-on-glucose-metabolism-100272246","NCT02823665","The Effects of Bariatric Surgeries on Glucose Metabolism","Inclusion Criteria:\n\n* Hypoglycemic RYGB patients with documented blood glucose level \\\u003C50 mg\u002Fdl\n* Asymptomatic individuals with bariatric surgery\n* Healthy non-surgical patients with no personal history of diabetes\n* Subjects must physically be able to come to our clinical research center Cedars-Sinai Medical Center\n\nExclusion Criteria:\n\n* Active heart, lung, liver, gastrointestinal or kidney disease; unable to give informed consent; pregnancy; uncontrolled high blood pressure or high cholesterol; significant anemia (hemoglobin \\\u003C11g\u002FdL); prisoners or institutionalized individuals; type 2 diabetes mellitis; development of any serious medical or psychiatric illness during recruitment or studies;\n* RYGB patients will be disqualified if they have gastric outlet obstruction or severe diarrhea.\n* Healthy non-surgical patients with personal history of diabetes\n\nFor administration of atropine, the following exclusions also apply:\n\n* History of glaucoma\n* Uncontrolled hypertension (any subjects with BP\\>140\u002F90 and history of dyslipidemia\n* Taking any medication that might interact with atropine and cannot be stopped will be excluded from the study)\n* Myasthenia gravis\n* Brain pathology\n* Enlarged prostate in men",{"count":223,"type":23},[352],"EARLY_PHASE1","The purpose of this study is learn the effect of gastric bypass surgery and sleeve gastrectomy on glucose metabolism mediated by neural and hormonal factors initiated after eating.",[355,356,29,357],"Post Bariatric Surgery","Gastric Bypass","Hypoglycemia After Gastric Bypass",[359,360,34,361],"gastric bypass surgery","Hypoglycemia","glucose tolerance","2025-09-08",{"date":364,"type":42},"2025-09-09",{"date":366,"type":4},"2015-07",{"date":368,"type":23},"2027-08",{"name":370,"class":49},"The University of Texas Health Science Center at San Antonio",{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":378,"enrollmentInfo":379,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":381,"conditions":382,"keywords":386,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":100},"100595497","vestibular-function-in-obesity-100595497","NCT07033221","Vestibular Function in Obesity","Evaluation of the Effect of Bariatric Surgery on the Vestibular System in Obese Patients.","Inclusion Criteria:\n\n1. The native language must be Turkish\n2. The participant must be between the ages of 18-60\n3. The participant must be suitable for bariatric surgery (BMI ≥40 kg\u002Fm2)\n4. Not have any previous vestibular diagnosis\n5. Not have any problems such as joints, muscles, or walking\n\nExclusion Criteria:\n\nIndividuals with additional disabilities, neurological problems, vestibulopathy, joint, muscle or walking disorders will not be included in the study.","60 Years",{"count":380,"type":23},30,"Previous studies have demonstrated that obesity negatively affects the human vestibular system. However, whether improvement in vestibular function occurs following the resolution of obesity remains an area requiring further investigation. Therefore, the investigators aimed to assess and analyze vestibular system functions in patients scheduled for bariatric surgery, both before the surgery, after the surgery, and following significant weight loss.\n\nParticipants aged between 18 and 60 years who meet the inclusion criteria will be enrolled in the study. Initially, participants will undergo medical history assessment and Body Mass Index (BMI) measurement. The enrolled participants will be evaluated using the following tests at three different time points-preoperatively, at the 1st month postoperatively, and at the 6th month postoperatively: Video Head Impulse Test (vHIT), static posturography test, Berg Balance Scale, SF-12 Quality of Life Scale, and the Activity-specific Balance Confidence (ABC) Scale.\n\nAlthough obesity has been shown to be associated with impaired postural balance, studies evaluating the direct effect of BMI on postural sway are limited. The aim of our study is to assess the vestibular system in obese patients before and after bariatric surgery. Through this, the investigators hope to contribute to the literature by providing balance assessments in individuals with obesity",[182,383,384,385,29],"Vestibular Function Disorder","Balance Assessment","Balance Impairment",[34,387,388,389],"balance in obese patients","vestibular function after sleeve gastrectomy","vestibulopathy in and obesity","2025-06-13",{"date":392,"type":42},"2025-06-24",{"date":394,"type":42},"2025-04-05",{"date":396,"type":23},"2026-06-01",{"name":398,"class":49},"Istanbul Aydın University",{"id":400,"slug":401,"hasResults":11,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":11,"sex":18,"minAge":109,"maxAge":407,"enrollmentInfo":408,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":410,"conditions":411,"keywords":412,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":100},"100535895","alcohol-after-bariatric-surgery-2-100535895","NCT06257771","Alcohol After Bariatric Surgery 2","Pharmacokinetics and Responses to Alcohol After Bariatric Surgery","ABS2","Inclusion Criteria:\n\n* Surgery groups:\n\n  * Male and female, 21-64 yrs. of age\n  * Drink at least 1 standard drink per month but no more than 7 per week (women or \\> 14 for men)\n  * Underwent SG surgery 1-5 years ago\n\nNon-surgery control group\n\n* Male and female who did not undergo bariatric surgery\n* Age , BMI, race , and alcohol pattern of consumption equivalent to participants in the SG surgery groups\n\nExclusion Criteria:\n\n* For all groups (surgery and non-surgery groups)\n\n  * Smoking or having quit smoking less than 2 months ago\n  * Pregnant or breastfeeding\n  * Taking any medications that might affect alcohol metabolism\n  * Anemia\n  * Gastritis, colitis, Crohn's Disease, malabsorptive diseases, inflammatory diseases, liver disease, kidney disease, cancer less than five years ago, stroke, or severe organ dysfunction\n  * Body weight \\>450 pounds (because of a limit on body composition machine)\n  * Alcohol use disorder\n  * Regular use of drugs with addiction potential or regular misuse of substances\n  * Abnormality on EKG as determined by a study physician to present a safety risk","64 Years",{"count":409,"type":23},88,"The goal of this observational study is to learn how the body processes ingested alcohol and how alcohol affects mood and blood sugar in both men and women after undergoing sleeve gastrectomy. The main question\\[s\\]it aims to answer are:\n\n* Are there differences in the way that ingested alcohol is handled in men versus women after sleeve gastrectomy?\n* What is the consequence of drinking alcohol on an empty stomach versus after a meal on blood sugar control after undergoing sleeve gastrectomy?\n\nParticipants will participate in two types of alcohol tests (alcohol given orally or administered intravenously) after not eating anything overnight or after having a meal.\n\nResearchers will compare men and women who underwent sleeve gastrectomy with men and women who had no surgery, are of similar age and body composition, and have similar alcohol intake patterns.",[29],[413,414,360,415],"Alcohol metabolism","Bariatric surgery","Metabolic surgery","2025-03-07",{"date":418,"type":42},"2025-03-11",{"date":420,"type":42},"2024-07-31",{"date":422,"type":23},"2028-08",{"name":424,"class":49},"University of Illinois at Urbana-Champaign",{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":432,"targetDuration":4,"studyType":58,"phases":434,"briefSummary":435,"conditions":436,"keywords":439,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":452,"locationsCount":194},"100575092","morbid-obesity-and-severe-knee-osteoarthritis---which-should-be-treated-first-100575092","NCT06767787","Morbid Obesity and Severe Knee Osteoarthritis - Which Should Be Treated First?","Morbid Obesity and Severe Knee Osteoarthritis - Which Should Be Treated First? A Randomized Cross-over Study","Inclusion Criteria:\n\n* BMI \\> or = 35, on surgical waitlist for a total knee arthroplasty and laparoscopic sleeve gastrectomy\n\nExclusion Criteria:\n\n* a history of revision surgery, surgery for neoplastic disease, significant mental illness, ASA class \\> 3 denoting absence of significant impact of comorbidities, and previous esophagogastric surgery.",{"count":433,"type":23},142,[60],"The goal of this study is to determine whether undergoing bariatric surgery before knee replacement leads to better outcomes compared to undergoing knee replacement before bariatric surgery. Our secondary goal is to compare complication rates between these groups to determine if there is a difference based on the order of the two procedures.\n\nParticipants will be randomly placed in one of two groups, with each undergoing both procedures but in opposite order. Quality of life will be assessed via questionnaires before and between each procedure, and rates of complications will also be documented to compare their rates between groups.",[437,438,29],"Osteoarthritis of Knee","Arthroplasties, Knee Replacement",[440,441,442,443,444,445],"knee osteoarthritis","bariatric surgery","laparoscopic sleeve gastrectomy","knee replacement","knee arthroplasty","obesity","2025-01-28",{"date":448,"type":42},"2025-01-30",{"date":450,"type":23},"2025-02",{"date":265,"type":23},{"name":453,"class":49},"Memorial University of Newfoundland"]